Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Healthcare Advertising Agencies

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Comment by Busyzzindahouseon Dec 02, 2016 3:07pm

27 Views

Post# 25548224

RE:RE:RE:RE:RE:Busyzzz in da houseeee

Orbie baby.... .tell me ur riding this up.......

Orbital14 wrote: Hey Busy I think you are mistaken on the article, had nothing to do with NF or the other companies. Was just a database of all the producers in Washington and their YTD sales. Shows how big the Washington market is and what NF is up against in terms of number of growers they have to sign up.

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages